Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07493122

PHASE1

Study of IMC-S118AI in Type 1 Diabetes

Sponsor: Immunocore Ltd

View on ClinicalTrials.gov

Summary

This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.

Official title: A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

154

Start Date

2026-04

Completion Date

2030-11

Last Updated

2026-03-25

Healthy Volunteers

Conditions

Type 1 Diabetes Type 1 Diabetes (T1D)Diabetes Type 1

Interventions

BIOLOGICAL

IMC-S118AI

IMC-S118AI solution for infusion/injection